Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma

Thumbnail
Date
2015-04
ICR Author
Boyle, Eileen Mary
Type
Other
Metadata
Show full item record
Abstract
Introduction: The current treatment approach of high-grade non-Hodgkin lymphoma (NHL) relies to a large extent on anthracycline-based regimens yielding cure rates in similar to 65 - 75% of patients. Despite being highly effective, these regimens are associated with significant long-term toxicity with a cumulative 10-year incidence of cardiovascular disease of 22%. Moreover, for the 25 - 35% of patients who fail first-line therapy there has been very little progress in terms of salvage regimens over the past 15 years. Re-treatment with anthracyclines-based regimens was, until now, not an option given the extensive cardiac toxicity of these agents. Pixantrone dimaleate (Pixantrone) is a novel anthracycline-like drug that offers an interesting alternative for the treatment of aggressive NHL. Areas covered: This article provides an overview of treatment-related cardiac toxicity in NHL, the pharmacology of Pixantrone and the evidence supporting its use in NHL. Expert opinion: Pixantrone is a potential alternative agent with a favorable safety profile for the treatment of relapsed and refractory NHL patients. It might benefit from combinations strategies and further development in the elderly and frail population.
URI
https://repository.icr.ac.uk/handle/internal/2079
Collections
  • Clinical Studies
  • Molecular Pathology
Subject
anthracyclines cardiotoxicity lymphoma Pixantrone B-CELL LYMPHOMA ADRIAMYCIN CARDIOTOXICITY PHASE-I AZA-ANTHRACENEDIONE RISK-FACTORS DOXORUBICIN CHOP MITOXANTRONE BBR-2778 CARDIOMYOPATHY
Research team
Molecular Haematology (including Cytogenetics Group and Cell Markers)
Language
eng
License start date
2015-04
Citation
2015, pp. 601 - 607

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.